PTC THERAPEUTICS INC
For the period ended Mar 31, 2024. Filed Apr 25, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 25, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Arrangements
A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.
Transactions in Company securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in Company securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of Company securities adopted orterminated by our directors and officers that is either (1) a contract, instruction
or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement”, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Name(Title) | Action Taken(Date of Action) | Type of TradingArrangement | Nature of TradingArrangement | Duration of TradingArrangement | Aggregate Numberof Securities |
|---|---|---|---|---|---|
| Matthew Klein(Chief Executive Officer) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2028 | Indeterminable (1) |
| Pierre Gravier(Chief Financial Officer) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2028 | Indeterminable (1) |
| Pierre Gravier(Chief Financial Officer) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2026 | Indeterminable (1) |
| Neil Almstead(Chief Technical Operations Officer) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2028 | Indeterminable (1) |
| Neil Almstead(Chief Technical Operations Officer) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2026 | Indeterminable (1) |
| Mark Boulding(EVP & Chief Legal Officer) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2028 | Indeterminable (1) |
| Mark Boulding(EVP & Chief Legal Officer) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2026 | Indeterminable (1) |
|---|---|---|---|---|---|
| Lee Golden(EVP & Chief Medical Officer) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2028 | Indeterminable (1) |
| Lee Golden(EVP & Chief Medical Officer) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2026 | Indeterminable (1) |
| Eric Pauwels(Chief Business Officer) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2028 | Indeterminable (1) |
| Eric Pauwels(Chief Business Officer) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2026 | Indeterminable (1) |
| Christine Utter(SVP,Chief Accounting Officer and Head of People Services) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2028 | Indeterminable (1) |
| Christine Utter(SVP,Chief Accounting Officer and Head of People Services) | Adoption(February 15, 2024) | Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on February 15, 2024 | Sale | Until final settlement of RSUs on or around February 15, 2026 | Indeterminable (1) |
|---|
(1) The number of shares subject to this RSU grant that will be sold to satisfy applicable tax withholding obligations upon vesting is unknown as the number will vary based on the extent to which vesting conditions are satisfied and the market price of the Company’s common stock at the time of settlement. This trading arrangement provides for the automatic sale of shares that would otherwise be issuable on each settlement date of the RSU in an amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable withholding obligation.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.